Profound Medical Corp. (NASDAQ: PROF) Stock Competitors & Peer Comparison
See PROF's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PROF and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PROF | $5.74 | -2.55% | 208.4M | -5.85 | -$0.98 | N/A |
| ABT | $103.49 | -0.23% | 179.1B | 19.87 | $5.21 | +2.40% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $89.30 | -1.62% | 114.3B | 16.15 | $5.53 | +3.21% |
| SYK | $273.40 | -0.61% | 104.8B | 20.42 | $13.39 | +1.28% |
| BSX | $44.62 | -0.67% | 66.4B | 14.40 | $3.10 | N/A |
| EW | $86.82 | -2.21% | 50B | 32.15 | $2.70 | N/A |
| DXCM | $87.73 | -2.01% | 33.1B | 34.40 | $2.55 | N/A |
| GEHC | $66.09 | -0.27% | 29.9B | 14.49 | $4.56 | +0.21% |
| PHG | $24.45 | -2.08% | 23.9B | 13.97 | $1.75 | +4.04% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
PROF vs ABT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ABT has a market cap of 179.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ABT trades at $103.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ABT's P/E ratio is 19.87. In terms of profitability, PROF's ROE is -0.56%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PROF is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
PROF vs BSX-PA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PROF's ROE is -0.56%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PROF is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
PROF vs MDT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, MDT has a market cap of 114.3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while MDT trades at $89.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas MDT's P/E ratio is 16.15. In terms of profitability, PROF's ROE is -0.56%, compared to MDT's ROE of +0.11%. Regarding short-term risk, PROF is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
PROF vs SYK Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SYK has a market cap of 104.8B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SYK trades at $273.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SYK's P/E ratio is 20.42. In terms of profitability, PROF's ROE is -0.56%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PROF is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
PROF vs BSX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BSX has a market cap of 66.4B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BSX trades at $44.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BSX's P/E ratio is 14.40. In terms of profitability, PROF's ROE is -0.56%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PROF is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
PROF vs EW Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, EW has a market cap of 50B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while EW trades at $86.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas EW's P/E ratio is 32.15. In terms of profitability, PROF's ROE is -0.56%, compared to EW's ROE of +0.10%. Regarding short-term risk, PROF is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for PROF.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
PROF vs DXCM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, DXCM has a market cap of 33.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while DXCM trades at $87.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas DXCM's P/E ratio is 34.40. In terms of profitability, PROF's ROE is -0.56%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PROF is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for PROF.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
PROF vs GEHC Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, GEHC has a market cap of 29.9B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while GEHC trades at $66.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas GEHC's P/E ratio is 14.49. In terms of profitability, PROF's ROE is -0.56%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PROF is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PROF.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
PROF vs PHG Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, PHG has a market cap of 23.9B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while PHG trades at $24.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas PHG's P/E ratio is 13.97. In terms of profitability, PROF's ROE is -0.56%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PROF is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PROF.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
PROF vs ZBH Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ZBH trades at $90.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ZBH's P/E ratio is 10.72. In terms of profitability, PROF's ROE is -0.56%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PROF is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
PROF vs ABMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PROF's ROE is -0.56%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PROF is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
PROF vs PEN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while PEN trades at $319.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas PEN's P/E ratio is 83.37. In terms of profitability, PROF's ROE is -0.56%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PROF is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
PROF vs SWAV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PROF's ROE is -0.56%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PROF is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
PROF vs SNN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SNN trades at $26.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SNN's P/E ratio is 18.10. In terms of profitability, PROF's ROE is -0.56%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PROF is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
PROF vs ALGN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ALGN has a market cap of 10.6B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ALGN trades at $148.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ALGN's P/E ratio is 13.51. In terms of profitability, PROF's ROE is -0.56%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PROF is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
PROF vs BIO-B Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BIO-B has a market cap of 10.3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BIO-B trades at $374.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BIO-B's P/E ratio is -65.99. In terms of profitability, PROF's ROE is -0.56%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PROF is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
PROF vs BIO Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BIO trades at $378.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BIO's P/E ratio is 40.83. In terms of profitability, PROF's ROE is -0.56%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PROF is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
PROF vs GMED Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, GMED has a market cap of 10B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while GMED trades at $73.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas GMED's P/E ratio is 16.66. In terms of profitability, PROF's ROE is -0.56%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PROF is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for PROF.Check GMED's competition here
Insulet Corp. (NASDAQ: PODD)
PROF vs PODD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, PODD has a market cap of 9.5B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while PODD trades at $136.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas PODD's P/E ratio is 23.25. In terms of profitability, PROF's ROE is -0.56%, compared to PODD's ROE of +0.27%. Regarding short-term risk, PROF is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
PROF vs MASI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas MASI's P/E ratio is 44.43. In terms of profitability, PROF's ROE is -0.56%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PROF is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PROF.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
PROF vs BRKR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BRKR trades at $59.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BRKR's P/E ratio is 29.98. In terms of profitability, PROF's ROE is -0.56%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PROF is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BRKR's competition here
Glaukos Corporation (NYSE: GKOS)
PROF vs GKOS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, GKOS has a market cap of 9.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while GKOS trades at $153.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas GKOS's P/E ratio is -178.48. In terms of profitability, PROF's ROE is -0.56%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PROF is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for PROF.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKRP)
PROF vs BRKRP Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BRKRP trades at $439.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BRKRP's P/E ratio is 238.95. In terms of profitability, PROF's ROE is -0.56%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PROF is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
PROF vs HAE Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while HAE trades at $106.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas HAE's P/E ratio is 21.32. In terms of profitability, PROF's ROE is -0.56%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PROF is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for PROF.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
PROF vs NARI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas NARI's P/E ratio is -59.24. In terms of profitability, PROF's ROE is -0.56%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PROF is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
PROF vs ITGR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ITGR trades at $126.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ITGR's P/E ratio is 19.89. In terms of profitability, PROF's ROE is -0.56%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PROF is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
PROF vs LIVN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while LIVN trades at $77.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas LIVN's P/E ratio is 18.33. In terms of profitability, PROF's ROE is -0.56%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PROF is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
PROF vs IRTC Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while IRTC trades at $111.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas IRTC's P/E ratio is -259.88. In terms of profitability, PROF's ROE is -0.56%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PROF is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for PROF.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
PROF vs AXNX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PROF's ROE is -0.56%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PROF is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
PROF vs TMDX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while TMDX trades at $87.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas TMDX's P/E ratio is 44.16. In terms of profitability, PROF's ROE is -0.56%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PROF is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
PROF vs NEOG Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while NEOG trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas NEOG's P/E ratio is 48.46. In terms of profitability, PROF's ROE is -0.56%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PROF is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NEOG's competition here
Butterfly Network, Inc. (NYSE: BFLY)
PROF vs BFLY Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BFLY trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BFLY's P/E ratio is -38.31. In terms of profitability, PROF's ROE is -0.56%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PROF is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BFLY's competition here
AxoGen, Inc. (NASDAQ: AXGN)
PROF vs AXGN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while AXGN trades at $43.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas AXGN's P/E ratio is 114.00. In terms of profitability, PROF's ROE is -0.56%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PROF is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
PROF vs UFPT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while UFPT trades at $287.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas UFPT's P/E ratio is 29.35. In terms of profitability, PROF's ROE is -0.56%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PROF is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
PROF vs NUVA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PROF's ROE is -0.56%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PROF is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
PROF vs INSP Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while INSP trades at $69.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas INSP's P/E ratio is 30.41. In terms of profitability, PROF's ROE is -0.56%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PROF is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for PROF.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
PROF vs ESTA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ESTA trades at $67.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ESTA's P/E ratio is -53.78. In terms of profitability, PROF's ROE is -0.56%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PROF is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
PROF vs NVCR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while NVCR trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas NVCR's P/E ratio is -12.50. In terms of profitability, PROF's ROE is -0.56%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PROF is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
PROF vs ATEC Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ATEC trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ATEC's P/E ratio is -167.17. In terms of profitability, PROF's ROE is -0.56%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PROF is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
PROF vs CNMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CNMD trades at $45.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CNMD's P/E ratio is 10.07. In terms of profitability, PROF's ROE is -0.56%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PROF is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
PROF vs HSKA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PROF's ROE is -0.56%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PROF is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PROF.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
PROF vs IART Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while IART trades at $15.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas IART's P/E ratio is 6.58. In terms of profitability, PROF's ROE is -0.56%, compared to IART's ROE of -0.01%. Regarding short-term risk, PROF is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for PROF.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
PROF vs AVNS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PROF's ROE is -0.56%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PROF is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PROF.Check AVNS's competition here
Artivion, Inc. (NYSE: AORT)
PROF vs AORT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while AORT trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas AORT's P/E ratio is 39.20. In terms of profitability, PROF's ROE is -0.56%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PROF is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check AORT's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
PROF vs TNDM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while TNDM trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas TNDM's P/E ratio is -17.61. In terms of profitability, PROF's ROE is -0.56%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PROF is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for PROF.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
PROF vs SILK Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SILK's P/E ratio is -18.96. In terms of profitability, PROF's ROE is -0.56%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PROF is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
PROF vs IRMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while IRMD trades at $86.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas IRMD's P/E ratio is 43.39. In terms of profitability, PROF's ROE is -0.56%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PROF is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
PROF vs FNA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas FNA's P/E ratio is -19.83. In terms of profitability, PROF's ROE is -0.56%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PROF is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PROF.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
PROF vs ENOV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ENOV trades at $18.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ENOV's P/E ratio is 5.22. In terms of profitability, PROF's ROE is -0.56%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PROF is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
PROF vs PRCT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while PRCT trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas PRCT's P/E ratio is -9.32. In terms of profitability, PROF's ROE is -0.56%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PROF is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check PRCT's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
PROF vs BBNX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BBNX has a market cap of 998.3M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BBNX trades at $22.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BBNX's P/E ratio is -13.45. In terms of profitability, PROF's ROE is -0.56%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PROF is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BBNX's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
PROF vs LMRI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, LMRI has a market cap of 974.3M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while LMRI trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas LMRI's P/E ratio is -19.73. In terms of profitability, PROF's ROE is -0.56%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PROF is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for PROF.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
PROF vs BVS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BVS has a market cap of 922.1M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BVS trades at $13.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BVS's P/E ratio is 17.91. In terms of profitability, PROF's ROE is -0.56%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PROF is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
PROF vs CBLL Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CBLL has a market cap of 896.2M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CBLL trades at $23.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CBLL's P/E ratio is -13.42. In terms of profitability, PROF's ROE is -0.56%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PROF is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for PROF.Check CBLL's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
PROF vs CSII Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CSII's P/E ratio is -20.83. In terms of profitability, PROF's ROE is -0.56%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PROF is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PROF.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
PROF vs SIBN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SIBN has a market cap of 824.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SIBN trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SIBN's P/E ratio is -54.71. In terms of profitability, PROF's ROE is -0.56%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PROF is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
PROF vs INMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, INMD has a market cap of 815.7M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while INMD trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas INMD's P/E ratio is 9.85. In terms of profitability, PROF's ROE is -0.56%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PROF is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
PROF vs VREX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while VREX trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas VREX's P/E ratio is 19.42. In terms of profitability, PROF's ROE is -0.56%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PROF is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
PROF vs AHCO Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, AHCO has a market cap of 775.5M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while AHCO trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas AHCO's P/E ratio is 11.63. In terms of profitability, PROF's ROE is -0.56%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PROF is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for PROF.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
PROF vs AVR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, AVR has a market cap of 740.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while AVR trades at $7.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas AVR's P/E ratio is -3.93. In terms of profitability, PROF's ROE is -0.56%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PROF is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for PROF.Check AVR's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
PROF vs CTKB Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CTKB has a market cap of 733.5M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CTKB trades at $5.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CTKB's P/E ratio is -30.09. In terms of profitability, PROF's ROE is -0.56%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PROF is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for PROF.Check CTKB's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
PROF vs SSII Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SSII has a market cap of 622.4M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SSII trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SSII's P/E ratio is -51.83. In terms of profitability, PROF's ROE is -0.56%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PROF is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for PROF.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
PROF vs SRDX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PROF's ROE is -0.56%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PROF is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
PROF vs APEN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas APEN's P/E ratio is -9.43. In terms of profitability, PROF's ROE is -0.56%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PROF is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
PROF vs KIDS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, KIDS has a market cap of 573.5M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while KIDS trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas KIDS's P/E ratio is -18.92. In terms of profitability, PROF's ROE is -0.56%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PROF is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for PROF.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
PROF vs DCTH Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, DCTH has a market cap of 551M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while DCTH trades at $15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas DCTH's P/E ratio is 1596.00. In terms of profitability, PROF's ROE is -0.56%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PROF is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for PROF.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
PROF vs ZIMV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PROF's ROE is -0.56%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PROF is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
PROF vs CERS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CERS has a market cap of 524M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CERS trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CERS's P/E ratio is -86.38. In terms of profitability, PROF's ROE is -0.56%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PROF is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for PROF.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
PROF vs TCMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, TCMD has a market cap of 505.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while TCMD trades at $22.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas TCMD's P/E ratio is 20.77. In terms of profitability, PROF's ROE is -0.56%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PROF is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
PROF vs NPCE Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, NPCE has a market cap of 484.5M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while NPCE trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas NPCE's P/E ratio is -24.93. In terms of profitability, PROF's ROE is -0.56%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PROF is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NPCE's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
PROF vs SGHT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SGHT has a market cap of 462.5M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SGHT trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SGHT's P/E ratio is -15.18. In terms of profitability, PROF's ROE is -0.56%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PROF is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SGHT's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PROF vs CLPT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CLPT has a market cap of 448.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CLPT trades at $14.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CLPT's P/E ratio is -12.69. In terms of profitability, PROF's ROE is -0.56%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PROF is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CLPT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
PROF vs PACB Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, PACB has a market cap of 437.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while PACB trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas PACB's P/E ratio is -3.44. In terms of profitability, PROF's ROE is -0.56%, compared to PACB's ROE of -49.62%. Regarding short-term risk, PROF is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for PROF.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
PROF vs SENS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SENS has a market cap of 416.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SENS trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SENS's P/E ratio is -4.47. In terms of profitability, PROF's ROE is -0.56%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PROF is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
PROF vs OFIX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, OFIX has a market cap of 371.1M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while OFIX trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas OFIX's P/E ratio is -5.98. In terms of profitability, PROF's ROE is -0.56%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PROF is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check OFIX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
PROF vs SMLR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PROF's ROE is -0.56%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PROF is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
PROF vs TLSI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, TLSI has a market cap of 307.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while TLSI trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas TLSI's P/E ratio is -2.98. In terms of profitability, PROF's ROE is -0.56%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PROF is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for PROF.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
PROF vs CV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CV has a market cap of 302.3M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CV trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CV's P/E ratio is -9.60. In terms of profitability, PROF's ROE is -0.56%, compared to CV's ROE of -1.78%. Regarding short-term risk, PROF is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for PROF.Check CV's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
PROF vs CATX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, CATX has a market cap of 298.4M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while CATX trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas CATX's P/E ratio is -1.97. In terms of profitability, PROF's ROE is -0.56%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PROF is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
PROF vs TMCI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while TMCI trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas TMCI's P/E ratio is -4.80. In terms of profitability, PROF's ROE is -0.56%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PROF is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for PROF.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
PROF vs RCEL Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, RCEL has a market cap of 272M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while RCEL trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas RCEL's P/E ratio is -7.60. In terms of profitability, PROF's ROE is -0.56%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PROF is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for PROF.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PROF vs INFU Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, INFU has a market cap of 257.5M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while INFU trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas INFU's P/E ratio is 31.12. In terms of profitability, PROF's ROE is -0.56%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PROF is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for PROF.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
PROF vs MGRM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PROF's ROE is -0.56%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PROF is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PROF.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
PROF vs ELMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ELMD has a market cap of 229.8M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ELMD trades at $27.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ELMD's P/E ratio is 21.18. In terms of profitability, PROF's ROE is -0.56%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PROF is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
PROF vs NVRO Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PROF's ROE is -0.56%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PROF is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NVRO's competition here
RxSight, Inc. (NASDAQ: RXST)
PROF vs RXST Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, RXST has a market cap of 200.8M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while RXST trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas RXST's P/E ratio is -4.29. In terms of profitability, PROF's ROE is -0.56%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PROF is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for PROF.Check RXST's competition here
Neuronetics, Inc. (NASDAQ: STIM)
PROF vs STIM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, STIM has a market cap of 200.4M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while STIM trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas STIM's P/E ratio is -6.55. In terms of profitability, PROF's ROE is -0.56%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PROF is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for PROF.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
PROF vs BSGM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PROF's ROE is -0.56%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PROF is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
PROF vs MDGS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PROF's ROE is -0.56%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PROF is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PROF.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
PROF vs FOCL Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, FOCL has a market cap of 177.7M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while FOCL trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas FOCL's P/E ratio is -4.58. In terms of profitability, PROF's ROE is -0.56%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PROF is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for PROF.Check FOCL's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
PROF vs QIPT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PROF's ROE is -0.56%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PROF is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check QIPT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
PROF vs LUCD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, LUCD has a market cap of 160M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while LUCD trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas LUCD's P/E ratio is -2.27. In terms of profitability, PROF's ROE is -0.56%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PROF is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check LUCD's competition here
Quantum-Si incorporated (NASDAQ: QSI)
PROF vs QSI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, QSI has a market cap of 150.1M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while QSI trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas QSI's P/E ratio is -1.65. In terms of profitability, PROF's ROE is -0.56%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PROF is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for PROF.Check QSI's competition here
Quanterix Corporation (NASDAQ: QTRX)
PROF vs QTRX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, QTRX has a market cap of 148.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while QTRX trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas QTRX's P/E ratio is -1.24. In terms of profitability, PROF's ROE is -0.56%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PROF is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
PROF vs INGN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, INGN has a market cap of 137.8M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while INGN trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas INGN's P/E ratio is -5.59. In terms of profitability, PROF's ROE is -0.56%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PROF is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
PROF vs ICAD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PROF's ROE is -0.56%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PROF is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
PROF vs ECOR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ECOR has a market cap of 103M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ECOR trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ECOR's P/E ratio is -6.80. In terms of profitability, PROF's ROE is -0.56%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, PROF is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
PROF vs HJLI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas HJLI's P/E ratio is N/A. In terms of profitability, PROF's ROE is -0.56%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PROF is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for PROF.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
PROF vs ASXC Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 208.4M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, PROF is priced at $5.74 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -5.85, whereas ASXC's P/E ratio is -1.12. In terms of profitability, PROF's ROE is -0.56%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, PROF is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ASXC's competition here